Dr. Marcel A. BehrÂ鶹AV Health Centre Office Phone: (514) 934 1934 x42815 |
Research
Focus
Marcel Behr was the Founding Director of the Â鶹AV International TB Centre. He completed a BSc inÌýBiochemistry at the University of Toronto, an MD at Queen’s University and residency training in Internal Medicine, Infectious Diseases and Medical Microbiology at Â鶹AV. He also completed an MSc in Epidemiology and Biostatistics at Â鶹AVÌýand then did post-doctoral training in molecular epidemiology and bacterial genomics, with Peter Small, at Stanford University. He is currently a Professor of Medicine at Â鶹AV and Associate Director of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the Â鶹AV Health Centre (). InÌýaddition to research activities, he attends on the Infectious Diseases consult service, he works in the TB clinic of the MUHC and he directs the mycobacteriology laboratory of the OptiLab Grappe-CUSM.
Marcel’s research employs genomic methods to study the epidemiology and pathogenesis ofÌýTB and other mycobacterial infections. His research is supported by a Foundation GrantÌýfrom the CIHR and he also enjoys an active collaboration with the Structure-Based Drug Discovery Coalition () for the development of novel anti-mycobacterial treatments. He has published more than 200 peer-reviewed publications, reviews and book chapters. In recognition of his work, he has been elected to the American Society of Clinical Investigation and is a Fellow ofÌýthe Canadian Academy of Health Sciences, the Royal Society of Canada and the American Academy of Microbiology.
Keywords
Tuberculosis, BCG, molecular microbiology, genomics, molecular epidemiology, non-tuberculous mycobacteria, NOD2, N-glycolyl muramyl dipeptide
Selected Publications
- Pai M, Behr MA, Dowdy D,ÌýDjedda K, Divangahi M, Boehme C, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nature Reviews Disease Primers 2016 Oct 27;2:16076. doi:10.1038/nrdp.2016.76
-
ÌýBehr MA, Edelstein P, Ramakrishnan L. Revisiting timetable of tuberculosis. BMJ. 2018 Aug 23;362:k2738. doi: 10.1136/bmj.k2738.
-
ÌýDuffy SC, Srinivasan S, Schilling MA, Stuber T, Danchuk SN, Michael JS, Venkatesan M, Bansal N, Maan S, Jindal N, Chaudhary D, Dandapat P, Katani R, Chothe S, Veerasami M, Robbe-Austerman S, Juleff N, Kapur V, Behr MA. Reconsidering Mycobacterium bovis as a proxy for zoonotic tuberculosis: a molecular epidemiological surveillance study. Lancet Microbe. 2020 Jun;1(2):e66-e73. doi: 10.1016/S2666-5247(20)30038-0.
-
ÌýGhanem M, Dube J-Y, Wang J, McIntosh F, Houle D, Domenech P, Reed MB, Raman S, Buter J, Minnaard AJ, Moody DB, Behr MA. Heterologous production of 1-tuberculosinyladenosine in Mycobacterium kansasii models pathoevolution towards the transcellular lifestyle of Mycobacterium tuberculosis. mBio. 2020 Oct 20;11(5):e02645-20. doi: 10.1128/mBio.02645-20.
-
ÌýSullivan J, Lupien A, Kalthoff E, Hamela C, Taylor L, Munro K, Schmeing M, Kremer L, Behr AM. Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS Pathog. 2021 Oct 12;17(10):e1009965. doi:10.1371/journal.ppat.1009965.
External Links
Ìý